Loading
A phase 1/2 trial of [68Ga]Ga-DPI-4452 in renal cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, bladder & urothelial cancer, head and neck squamous cell carcinoma and triple-negative breast cancer, run by Lumara Bio Oncologics GmbH, now recruiting.
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05706129 by Lumara Bio Oncologics GmbH, with 270 participants planned, started 2023-03-14 and due to reach its primary completion in 2027-06. Interventions recorded: [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Colorectal cancer and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Renal cell carcinoma, Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC) and the tag pipeline.